health pharma news today obesity drugs glp-1 today A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio WHO recommends GLP-1 drugs for

100 This randomized placebo-controlled trial included 5380 patients and had a median follow-up of 18 months

Pharmacotherapy of weight-loss and obesity with a focus on GLP 1-receptor agonists

doi: 10.1016/j.transproceed.2024.11.016

GLP-1RAs compared to placebo In addition, the pooled results showed that first line use of GLP-1RAs has a significant predisposing effect on diarrhea (OR: 2.18, 95% CI: 1.32, 3.60

Some weeks you might deal with constipation from slowed motility

As experts continue to study the impact that GLP-1s have on health outcomes, state budgets, peoples lives and out-of-pocket costs, it is expected that the drugs will remain a topic of conversation among state lawmakers, Medicaid agencies, stakeholder groups and many others during the coming 2025 legislative session